Error: Could not add to watchlist. X
+ Watchlist

Catabasis Pharmaceuticals Inc

209:GR
Frankfurt
1.18
EUR
0.00
0.17%
As of 9:35 AM EDT 6/23/2017
Open
1.15
Day Range
1.15 - 1.18
Volume
0
Previous Close
1.18
52Wk Range
1.14 - 1.90
Before it's here, it's on the Bloomberg Terminal.
Learn More
Open
1.15
Day Range
1.15 - 1.18
Volume
0
Previous Close
1.18
52Wk Range
1.14 - 1.90
Current P/E Ratio (TTM)
-
Earnings per Share (USD) (TTM)
-
Market Cap (m EUR)
26.492
Shares Outstanding (m)
22.470
Price/Sales (TTM)
-
Dividend Indicated Gross Yield
-
Sector
Health Care
% Price Change
-0.33%
% Price Change
-0.39%

Related Videos

There are currently no related videos for this ticker. Please check back later.
There are currently no news stories for this ticker. Please check back later.
There are currently no press releases for this ticker. Please check back later.
Profile
Catabasis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. The Company's initial focus is on treatments for rare diseases, while also developing other product candidates for the treatment of serious lipid disorders.
Address
1 Kendall Square
Building 1400E, Suite B14202
Cambridge, MA 02139
United States
Phone
1-617-349-1971
  • Jill C Milne
    President/CEO/Co-Founder
  • Michael Jirousek "Mike"
    Chief Scientific Ofcr/Co-Founder
  • Andrew Nichols "Andy"
    Chief Scientific Officer
  • Ted Hibben
    Chief Business Officer
  • Deirdre A Cunnane
    Sr VP/Treasurer/Gen Cnsl
Show More